Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition constitutes a novel therapeutic target. Genomic data suggest...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Kurata, K, James-Bott, A, Tye, MA, Yamamoto, L, Samur, MK, Tai, Y-T, Dunford, J, Johansson, C, Senbabaoglu, F, Philpott, M, Palmer, C, Ramasamy, K, Gooding, S, Smilova, M, Gaeta, G, Guo, M, Christianson, JC, Payne, NC, Singh, K, Karagoz, K, Stokes, ME, Ortiz, M, Hagner, P, Thakurta, A, Cribbs, A, Mazitschek, R, Hideshima, T, Anderson, KC, Oppermann, U
Format:	Journal article
Sprache:	English
Veröffentlicht:	Springer Nature 2023

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Ähnliche Einträge